Xcout Intel
ALZpath, Inc.
ALZpath, Inc. is a diagnostic company that specializes in blood test-based detection for Alzheimer's disease. The company is headquartered in Carlsbad, California, and employs between 11 and 50 people.
Subscribe to see ALZpath, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ALZpath, Inc. at a glance
ALZpath, Inc. is a company headquartered in United States. Its most recent funding round raised $8.4M in July 2026. Xcout tracks 5 named people at ALZpath, Inc., including Mike Banville (CEO and President).
ALZpath, Inc. leadership
- Mike BanvilleCEO and President
- Micah BuehlerChief Financial Officer
- Jacob HunterChief Business Officer
- Jerre SteadCo-Founder, Chair
- Lee HonigbergVP of Research & Development
ALZpath, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $8.4M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent ALZpath, Inc. news
- FundingPrivate placement (Form D)
ALZpath, Inc. competitors
A few of ALZpath, Inc.'s closest competitors — see the full list of competitors and alternatives →
Digipath, Inc. is a biotechnology research company headquartered in Las Vegas, Nevada, providing testing and related services with a team of 11-50 employees.
Ceresti Health is a healthcare technology systems company that provides solutions to reduce hospitalizations and expand dementia caregiver support for families. The corporate office is located in Carlsbad, California.
NeuroQuest Development Center, Inc. is a biotechnology company that operates a development center located in North Charleston, South Carolina, and announced plans to begin US clinical validation trials for an Alzheimer's blood test.
C2N Diagnostics, LLC is a biotechnology company that develops blood-based diagnostic tests for neurodegenerative diseases, particularly Alzheimer’s disease. Its Precivity d tests use mass spectrometry-based plasma biomarkers and are intended for use by healthcare providers and researchers in evaluating patients for Alzheimer’s pathology.
Alzheon, Inc. is a clinical-stage biopharmaceutical company headquartered in Framingham, Massachusetts. Founded in 2013, the company is dedicated to developing a broad portfolio of investigational therapeutic products for neurodegenerative disorders, including Alzheimer's disease. Its research centers on advancing disease-modifying treatments for patients with cognitive decline.
Veravas Inc. develops diagnostic technology and testing solutions, including its proprietary VeraBIND platform, designed to reduce laboratory test interference and detect hard-to-find biomarkers. The company primarily serves clinicians, researchers, and patients by providing tools and assays focused on the early detection of complex conditions such as Alzheimer's disease and other dementias.
Get ALZpath, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on ALZpath, Inc. in Xcout Intel
- 5 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access